While the market is rebounding in November, with the S&P 500 up more than 5%, many great stocks continue to be battered and bruised. This mostly has to do with earnings reports. Companies that post better-than-expected financial results and offer bullish guidance are seeing their share prices soar, while companies that disappoint are seeing their
Once the post-COVID boom faded, many high-flying tech stocks plummeted, potentially creating opportunities for growth investors looking to position their portfolios for substantial gains. In my view, select beaten-down tech companies appear primed for massive upside if bought before the impending recovery. Of course, timing the bottom involves substantial risk, given the ongoing market turbulence.
Betting a few dollars on an exciting startup like electric vehicle (EV) manufacturer Mullen Automotive (NASDAQ:MULN) might seem harmless. Yet, I encourage you to find another investment than MULN stock. In all likelihood, Mullen Automotive will continue to disappoint its shareholders. Besides, the last thing you need in your account is a capital loss. Don’t get the
Much like many EV startups, Nio (NYSE:NIO) has sparked heated debate. The company has been burning billions of dollars every year, with revenue declining the past two quarters as losses mount. Meanwhile, the stock has plunged nearly 88% from early-2021 highs. Many wonder if Nio will stage a massive turnaround as revenue and earnings are
Some of Google and YouTube parent company Alphabet’s (NASDAQ:GOOG, NASDAQ:GOOGL) critics might claim that Alphabet is still playing catch-up in the generative artificial intelligence (AI) arms race. Yet, GOOG stock investors shouldn’t worry too much. Alphabet is relentlessly pushing the gen-AI envelope with new and upgraded products on a global scale. Like it or not, generative AI is
The article embarks on a transformative journey through the biotech frontier, where the listed companies stand as titans reshaping healthcare norms. The first one’s strategic collaboration with a multinational healthcare giant propels financial strength, unlocking accelerated milestones in key programs. The second one takes center stage with “Barzolvolimab,” a revolutionary monoclonal antibody targeting mast cell